rhenium 188-labeled anti-CD66 monoclonal antibody

Rhenium 188-labeled anti-CD66 monoclonal antibody is an experimental radiopharmaceutical combining a monoclonal antibody targeting the CD66 family of antigens (subtypes a, b, c, and e) with the radioactive isotope rhenium-188. The antibody delivers targeted radiation to the bone marrow, primarily for *radioimmunotherapy* as part of the conditioning regimen prior to hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The targeted nature of this therapy allows for increased radiation to malignant marrow and relatively lower exposure to non-target organs. Patients receiving this molecule in clinical studies demonstrated minimal infusion-related toxicity and no excess treatment-related mortality from the radioimmunoconjugate, with some risk of late renal toxicity. The product is investigated to *intensify pre-transplant conditioning*, with dosimetric planning performed ahead of administration to determine expected organ exposures. This drug is part of ongoing research and clinical trials for bone marrow ablation in hematologic malignancies[1][7].

Other names

188Re-labeled anti-CD66 monoclonal antibodyrhenium-188-anti-CD66 mAbrhenium188-anti-CD66 mAbrhenium 188-anti-CD66 mAb